Xalatan Patent Ruling
This article was originally published in The Pink Sheet Daily
A D.C. federal appeals court upheld a patent ruling that bars Par from launching its generic of Pfizer's glaucoma agent Xalatan before 2011
You may also be interested in...
Two of three Pfizer patents for the glaucoma treatment are valid, a Trenton, N.J. federal court says. If the court's ruling is affirmed on appeal, Par would lose any 180-day generic marketing exclusivity that attaches to the two valid patents.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.